Form 4: Humacyte Director Acquires Stock Options

Keith Anthony Jones, a director of Humacyte, Inc., acquired 75,000 stock options on June 13, 2024, exercisable over a four-year period.

Summary

• On June 13, 2024, Keith Anthony Jones, a director of Humacyte, Inc., acquired 75,000 stock options.
• The options have an exercise price of $7.20.
• The options vest in installments, with the first 25% becoming exercisable on June 13, 2025.
• Thereafter, 1/48 of the options will become exercisable monthly through June 13, 2028.
• The options expire on June 13, 2034.
• Following the transaction, Jones directly owns 75,000 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard executive compensation practices and aligns the director's interests with the company's long-term success.

Positives

• The acquisition of stock options by a director signals confidence in the company's future prospects.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedule of the options.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize and retain key personnel.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like Amgen, Gilead Sciences, and Biogen routinely grant stock options to their directors and officers as part of their overall compensation strategy.
• The vesting schedule and exercise price are typically determined based on industry benchmarks and the company's performance.

Stakeholder Impact

• The stock option grant could potentially increase shareholder value if the director's performance leads to company growth.
• The grant incentivizes the director to act in the best interests of the company and its shareholders.

Key Dates